ReviewInternational journal of obesity (2005)2026
Autophagy in hypothalamic POMC and AgRP neurons: mechanisms and therapeutic implications for obesity.
Review in International journal of obesity (2005), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is increasingly recognized as a disorder involving impaired central endocrine regulation in which hypothalamic nutrient sensing, leptin responsiveness, and intracellular quality control are closely intertwined. Within the arcuate nucleus, autophagy exerts divergent metabolic effects in the two principal appetite-regulating neuronal populations. In pro-opiomelanocortin (POMC) neurons, autophagy supports metabolic homeostasis by promoting alpha-melanocyte-stimulating hormone (α-MSH) production, preserving leptin and insulin sensitivity, and activating peripheral lipophagy; its disruption predisposes to hyperphagia, leptin resistance, and obesity-related metabolic dysfunction. In contrast, autophagy in agouti-related peptide (AgRP) neurons promotes feeding and energy conservation by maintaining AgRP expression, integrating ghrelin signals, and sensing peripheral fatty acids; its inhibition alleviates diet-induced obesity in mice. This review critically evaluates discrepancies among models based on the deletion of autophagy-related gene 5,7, and 12 (Atg5, Atg7, and Atg12), as well as differences arising from developmental versus adult manipulations, dietary paradigms, and the reliance of static autophagy markers. We further discuss how POMC and AgRP neuron autophagy may interact with broader hypothalamic and extra-hypothalamic networks, including basonuclin 2 (BNC2), steroidogenic factor 1 (SF1) neurons in the ventromedial hypothalamus (VMH), and paraventricular hypothalamic nucleus (PVH) pathways, as well as extra-hypothalamic components involving the brainstem, glial and tanycytic cells, and neurovascular interaction. Chaperone-mediated autophagy (CMA) has emerged as a potential pathway potentially linking saturated fatty acid exposure, LAMP2A-dependent proteostasis, and insulin responsiveness in hypothalamic neurons, although direct evidence remains limited. Because direct demonstration of altered autophagic flux in human POMC or AgRP neurons remains lacking, hypothalamic autophagy should currently be viewed as a mechanistic and translational research framework rather than a validated clinical target. Future therapies will likely require pathway-biased, neuron-type-specific, and circuit-aware modulation rather than global activation or inhibition of autophagy.
Identifiers
42768087What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.